BCLS Acquisition Corp. Price, Forecast, Insider, Ratings, Fundamentals & Signals

Boston--(business wire)--bcls acquisition corp. (the “company”) (nasdaq: blsa), a special purpose acquisition company, today announced that as of the close of business on october 26, 2022, the company’s publicly held class a ordinary shares, par value $0.0001 (the “public shares”), will be deemed cancelled and will represent only the right to receive their pro-rata share in the company’s trust account (“trust account”), because the company will not consummate an initial business combination within the time period required by its amended and restated memorandum and articles of association (the “articles”). as stated in the company’s articles and in the company’s registration statement on form s-1 (registration no...

Boston--(business wire)--bcls acquisition corp. (the “company”), a special purpose acquisition company formed for the purpose of entering into a combination with one or more businesses or entities, today announced the pricing of its initial public offering of 12,500,000 class a ordinary shares at a price of $10.00 per share. the class a ordinary shares will be listed on the nasdaq capital market and trade under the ticker symbol “blsa” beginning on october 22, 2020. while the company may pursue an acquisition opportunity in any business, industry, sector or geographical location, it intends to pursue investments, primarily based in north america and europe and selectively in other geographies, including asia and emerging markets, in biopharmaceutical, specialty pharmaceutical, medical device, diagnostics and enabling life science technology companies...